Form 4 for GOSS Gossamer Bio, Inc.
Accepted 2025-10-02 00:00:00 ET · period of report 2025-10-01 · accession 0001867872-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-02 | 2025-10-01 | GOSS | Aranda Richard | Chief Medical Off | A - Grant | $0.00 | +162.5K | 369.4K | +79% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-01 | A | A | 162,500 | $0.00 | 369,356 | D | — | — | (F1) Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer. |